Search

Your search keyword '"Jørgensen, Jan Trøst"' showing total 180 results
Start Over Author "Jørgensen, Jan Trøst"
180 results on '"Jørgensen, Jan Trøst"'

4. Contributors

Author

Albesa, Roger, primary, Aure, Mary Ann, additional, Auza, Carolina, additional, Bizzaro, Nicola, additional, Bradbury, Joanne, additional, Choi, May Y., additional, Deane, Kevin D., additional, Fritzler, Marvin J., additional, Hirschfield, Gideon M., additional, Hudson, Marie, additional, Jørgensen, Jan Trøst, additional, Kubassova, Olga, additional, MacMartin-Moglia, Kim, additional, Mahler, Michael, additional, Martin, Lily W., additional, Martinez-Prat, Laura, additional, Melus, Carlos, additional, Mieli-Vergani, Giorgina, additional, Norman, Gary L., additional, Prisco, Lauren C., additional, Rossin, Brenden, additional, Satoh, Minoru, additional, Sciascia, Savino, additional, Shaikh, Faiq, additional, Sparks, Jeffrey A., additional, Vergani, Diego, additional, Villalta, Danilo, additional, and Wu, Jungen Andrew, additional

Published
2021
Full Text
View/download PDF

12. List of Contributors

Author

Alturkistani, Abrar, primary, An, Juanjuan, additional, Benda, Norbert, additional, Bienfait, Karina, additional, Blackler, Adele R., additional, Bøgsted, Martin, additional, Brindley, David, additional, Broich, Karl, additional, Brøndum, Rasmus F., additional, Brunhoeber, Patrick, additional, Bureau, Matthew, additional, Car, Josip, additional, Carter, Alison, additional, Clarke, Tara, additional, Clements, June, additional, Cross, Darren, additional, Doble, Brett, additional, Dolled-Filhart, Marisa, additional, Domazetoski, Elena, additional, Duncan, Mark W., additional, ElGabry, Ehab A., additional, Ellison, Aaron R., additional, Emancipator, Kenneth, additional, Enzmann, Harald, additional, Farooq, Maria, additional, Feng, Janine, additional, Foley, Kimberley, additional, Generalov, Evgenii, additional, Go, Ning Fei, additional, Goltsov, Alexey, additional, Green, George A., additional, Hersom, Maria, additional, Honarpour, Narimon, additional, Iddamalgoda, Lahiru, additional, Ikeda, Masayuki, additional, Jenkins, Suzanne, additional, Jørgensen, Jan Trøst, additional, Kapadia, Monesh, additional, Karwowska, Sylwia, additional, Kuzulugil, Sebnem S., additional, Lam, Ching, additional, Lewis, Jason S., additional, Li, Jinbo, additional, Liesenfeld, Oliver, additional, Lopes, Gilberto, additional, Luo, Dee, additional, Meinert, Edward, additional, Meyer, Ralf, additional, Mistry, Amita, additional, Mitsakakis, Nicholas, additional, Mollerup, Jens, additional, Montalto, Michael C., additional, Murata, Lauren B., additional, Murtaza, Muhammed, additional, Nielsen, Karsten Bork, additional, Pant, Saumya, additional, Parker, Jayson L., additional, Pereira, Patrícia M.R., additional, Ramarao, Manjunath, additional, Rigl, Ted, additional, Schildgen, Oliver, additional, Schildgen, Verena, additional, Scholl, Catharina, additional, Scudder, Sidney A., additional, Seyfried, Donna, additional, Sharma, Abha, additional, Shimazawa, Rumiko, additional, Simon, Richard, additional, Singh, Shalini, additional, Sobol, Nicholas B., additional, Stanforth, David A., additional, Stingl, Julia, additional, Sundararajan, Vijayaraghava Seshadri, additional, Suravajhala, Prashanth, additional, Tosolini, Alessandra, additional, Tsou, Jeff, additional, Tully, Kathryn M., additional, Walk, Eric E., additional, Wu, Dianna, additional, Xu, Xiaolei, additional, and Yu, Karen, additional

Published
2019
Full Text
View/download PDF

40. Site-agnostic biomarker-guided oncology drug development.

Author

Jørgensen, Jan Trøst

Abstract

Advances within molecular diagnostics have enabled us to identify a number of oncogenic drivers across different cancers. Many cancers can now be divided into subgroups based on molecular characteristics, and an increasing number of targeted anticancer drugs have been developed together with a predictive biomarker assay using the drug-diagnostic codevelopment model. With the recent approval of entrectinib, larotrectinib, and pembrolizumab for site-agnostic indications, biomarker-guided drug development has entered into a new phase. The review focuses on the general principles of drug-diagnostic codevelopment, especially basket trials and site-agnostic drug development. Special attention is paid to entrectinib, larotrectinib, and pembrolizumab. The recent approval of entrectinib, larotrectinib, and pembrolizumab must be regarded as a paradigm shift in biomarker-guided oncology drug development. For a site-agnostic indication, it is important to have in mind the central role of the companion diagnostic (CDx), as the assay defines the 'disease' and the patient population to be treated. A number of site-agnostic drugs are currently in development and here, it is important that CDx assay development is given high priority, so an analytical and clinical validated assay is available at the time of drug approval. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Companion diagnostics:a tool to improve pharmacotherapy

Author

Jørgensen, Jan Trøst, Hersom, Maria, Jørgensen, Jan Trøst, and Hersom, Maria

Abstract

The variability of pharmacotherapy can be of a significant magnitude, and the main reason for this is often diseases heterogeneity. Patients who have similar diagnoses very often respond differently to the same pharmacological intervention, with great variability in both efficacy and safety outcome. Despite having discussed personalized medicine for more than a decade, we still see that most drug prescriptions for severe chronic diseases are largely based on 'trial and error' and not on solid biomarker data. However, with the advance of molecular diagnostics and a subsequent increased understanding of disease mechanisms, things are slowly changing. Within the last few years, we have seen an increasing number of predictive biomarker assays being developed to guide the use of targeted cancer drugs. This type of assay is called companion diagnostics and is developed in parallel to the drug using the drug-diagnostic co-development model. The development of companion diagnostics is a relatively new discipline and in this review, different aspects will be discussed including clinical and regulatory issues. Furthermore, examples of drugs, such as the ALK and PD-1/PD-L1 inhibitors, that have been approved recently together with a companion or complimentary diagnostic will be given.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results